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Abstract
Background: Bisphenol A (BPA) and phthalates are ubiquitous non-persistent endocrine disrupting chemicals
whose relation with infant birth size is not clearly understood.
Methods: We examined associations between maternal and paternal preconception urinary concentrations of total
BPA and 14 phthalate metabolites and birth size for 233 infants. Multiple linear regression models were used to
estimate parental quartiles of BPA and phthalates in relation to birth weight, length, head circumference, and
ponderal index with separate models run for each parent adjusting for age, smoking, body mass index, education,
alcohol, parity, and creatinine. Models also included an interaction term for each chemical and infant sex and were
further adjusted to include the other partner’s chemical concentrations.
Results: In maternal models adjusted for partner’s exposure and covariates, reductions in birth weight (range:
178-215 g; p < 0.05) were observed for the 2nd quartile of maternal monomethyl phthalate, mono-[(2-carboxymethyl)
hexyl] phthalate and mono-n-octyl phthalate when compared with the 1st quartiles. The 3rd quartile of monoethylhexyl
phthalate (mEHP) was also associated with a 200.16 g (95 % CI: -386.90, -13.42) reduction. Similar reductions in birth
weight were observed for the 2nd quartile of paternal mEHP (β = -191.93 g; 95 % CI: -381.61, -2.25). Additionally, select
maternal urinary metabolites were associated with decreased head circumference, birth length and gestational age.
However, paternal concentrations were generally associated with increased birth length and gestational age.
Conclusions: We observed some suggestion that preconception maternal and paternal urinary concentration of BPA
and specific phthalate metabolites may be associated with smaller birth size and increased gestational age, though the
findings appeared to be parent and chemical specific.
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Background
Bisphenol A (BPA) and phthalates are non-persistent
endocrine disrupting chemicals (EDCs) found in a
variety of commercial products. Specifically, BPA is used
in the production of polycarbonate plastics and epoxy
resins, e.g., plastic bottles, lining of food cans, and
thermal receipt papers [1]. Similarly, phthalates are
plasticizers found in many consumer products, including
but not limited to cosmetics, children’s toys, pharmaceu-
ticals and nutritional supplements [2]. Biomonitoring
data underscore their ubiquitous prevalence, with 93 %
and 75 % of the U.S. general population having detect-
able concentrations of BPA and phthalates, respectively
[3, 4]. In an analysis of urine samples collected on a
subset of pregnant women from the 2003-2004 National
Health and Nutritional Examination Survey (NHANES),
BPA was detected in 96 % of the samples and phthalates
were detected in 99-100 % of the samples [5]. Therefore,
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continual human exposure is probable, and the assess-
ment of possible human health effects is essential.
Despite a suggestive body of animal evidence, current
reviews conclude that studies on BPA and human health
are limited [6–8]. An evolving body of epidemiologic
research suggests that BPA may adversely affect human
fecundity as measured by diminished semen quality [9],
early blastocyst or embryonic development [10] and
reduced levels of estradiol and number of oocytes
retrieved [11] among women undergoing assisted repro-
ductive technologies. Regarding pregnancy outcomes,
maternal exposures have been associated with increased
odds of preterm birth [12], reductions in length of gesta-
tion [13–15], birth weight, length [16] and fetal growth
[17], suggesting a relation between parental exposures
and fetal development.
To date, research has largely relied upon prenatal urin-
ary concentrations and associated fetal/infant outcomes.
To our knowledge, there have been no previous efforts
focusing on parental preconception exposures to BPA
and phthalates, despite the couple dependent nature of
pregnancy. Such a study is important for helping to
more fully understand the implications of physiological
changes during pregnancy that may be associated with
the reported variability of chemical exposures during
this sensitive window of human development [18]. As
such, preconception concentrations may be more reflect-
ive of early pregnancy concentrations that characterize
women before they are typically recruited into preg-
nancy cohort studies. To date, few studies have focused
on parental preconception or early pregnancy exposures
other than a few focusing on persistent chemicals
reported to be associated with infant birth size outcomes
[19–21]. Other authors have noted the importance of
considering paternal exposures given their ability to
either directly impact sperm DNA or indirectly through
seminal fluid exposure [22]. Prompted by these data
gaps, we undertook an investigation of parental precon-
ception BPA and phthalate exposures in relation to
prospectively measured gestation and birth size, includ-
ing the joint analysis of parental exposures.
Materials and methods
Study design and subjects
The study population comprises 501 reproductive aged
couples who were recruited from16 counties in Mich-
igan and Texas between 2005 and 2009 with the explicit
purpose of assessing environmental influences on hu-
man fecundity and fertility, as previously described [23].
Couples were recruited upon discontinuing contracep-
tion for purposes of becoming pregnant. Inclusion criteria
were minimal: females aged 18-40 and males ≥18 years; in
a committed relationship; no physician diagnosis of
infertility/sterility; females had to have menstrual cycles
between 21-42 days without any injectable hormonal
contraceptives in the past year; and an ability to
communicate in English or Spanish. In-person inter-
views were conducted with each partner of the couple
to ascertain lifestyle and reproductive history followed
by standard anthropometric assessments to assess body
mass index (BMI) [24]. Couples were followed for up to
a year while trying for pregnancy, and women used
home pregnancy test kits on the day of expected
menstruation for the detection of pregnancy.
Among the 501 enrolled couples, 347 (69 %) had an
observed human chorionic gonadotropin confirmed
pregnancy of which 90 % occurred within 6 menstrual
cycles and the remaining 10 % in cycles 7-12 [25].
Furthermore, 233 (67 %) had a singleton live birth, with
a reported birth weight (exclusions for the present
analysis included 2 couples with twin live births and 1
couple with a twin gestation and a singleton live birth).
Pregnant women were followed daily through six post-
conception weeks, then monthly until either a pregnancy
loss or delivery. Institutional review board approvals
were obtained from all collaborating institutions; cou-
ples gave written informed consent prior to study
participation.
Biospecimens collection and exposure assessment
During the enrollment home visit, research assistants
instructed couples in the proper collection of urine sam-
ples for the quantification of BPA, phthalates, and
creatinine. Samples were transported on ice for process-
ing and shipment to the laboratory. Chemical analysis
was performed at the Wadsworth Center, New York
State Department of Health using an established proto-
col [26]. Specifically, urinary concentrations of total BPA
were quantified as nanograms/milliliter (ng/mL) by
enzymatic deconjugation, solid phase extraction and
high-performance liquid chromatography (HPLC), coupled
with API 2000 electrospray triple-quadrupole mass
spectrometry (MS/MS). Urinalysis was performed using
HPLC-MS/MS and an established protocol [27] for 14
phthalate metabolites: monomethyl phthalate (mMP),
monoethyl phthalate (mEP), mono-n-butyl phthalate
(mBP), mono (2-isobutyl phthalate) (miBP), monobenzyl
phthalate (mBzP), mono (2-ethyl-5-carboxyphentyl) phthal-
ate (mECPP), mono-[(2-carboxymethyl) hexyl] phthalate
(mCMHP), mono (2-ethyl-5-oxohexyl) phthalate (mEOHP),
mono (2-ethyl-5-hydroxyhexyl) phthalate (mEHHP), mono
(2-ethylhexyl) phthalate (mEHP), mono (3-carboxypropyl)
phthalate (mCPP), monocyclohexyl phthalate (mCHP),
mono-isononyl phthalate (mNP), and monooctyl
phthalate (mOP). Creatinine was quantified using a
Roche/Hitachi Model 912 clinical analyzer (Dallas, TX)
and the Creatinine Plus Assay. In addition, non-fasting
blood samples were collected from each partner to
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measure serum cotinine using liquid chromatography-
isotope dilution tandem mass spectrometry and as
reported in ng/mL [28].
Assessment of birth size
Following delivery, couples returned standardized birth
announcements that were included in the pregnancy jour-
nals women completed while pregnant. This data collection
form was designed for parents to report date-of-delivery,
infant sex, birth weight in pounds and ounces (n = 233);
length in -inches (n = 230); head circumference in inches
(n = 183); and date of delivery (n = 233). Weight was
converted to grams, and length and head circumference to
centimeters for analysis. Gestational age was defined as the
number of days from the day of ovulation as recorded on
fertility monitors that was estimated to be the day of con-
ception and date of delivery. We also estimated ponderal
indices (PIs) for 230 infants, which is similar to adult body
mass index and derived from the following formula: [birth
weight (grams)/birth length (cm3)] × 100. PIs are prox-
ies of infant adiposity and can be further categorized
in relation to growth symmetry: normal (2.20-3.00),
symmetrical (>3.00) and asymmetrical (<2.20) [29].
Statistical analysis
Univariate analyses were performed to assess all chem-
ical distributions and birth size outcomes. Machine-read
values for all chemicals were used to avoid biasing re-
gression estimates [30, 31]. Serum cotinine and urinary
creatinine concentrations were natural-log transformed
(ln) to approach more normal distributions. Geometric
means and corresponding 95 % confidence intervals
were estimated on ln-transformed chemical concentra-
tions. We modeled all chemical data in quartiles in light
of the non-normal distributions, absence of known lin-
ear relations with birth size and to aid in the interpret-
ation of findings. To minimize possible bias associated
with excluding individuals with missing data while main-
taining power, we imputed data for missing chemical expo-
sures stemming from insufficient urine for quantification
and relevant covariates (10 %) using data for the entire
cohort and Markov Chain Monte Carlo methods, under an
assumption of ‘missing at random’ [32, 33]. We defined
statistical significance as a two-sided p-value < 0.05.
Multiple linear regression models were used to esti-
mate the mean change in each birth outcome per quar-
tile of urinary chemical concentrations, relative to the
lowest quartile; birth outcomes were modeled separately
for each chemical and parent. Models were adjusted a
priori for creatinine (ng/mL), age (years), race/ethnicity,
body mass index (weight in kg/height in m2), education,
smoking (serum cotinine ng/mL), frequency of alcoholic
beverage consumption, maternal parity (number of live
births) conditioned on gravidity (number of pregnancies)
and infant gender. Models were re-run to test for poten-
tial interactions between each chemical and infant sex in
light of data suggesting possible gender susceptibilities
[34, 35]. Finally, models were further adjusted for the
other partner’s chemical concentration, smoking and
creatinine in light of pregnancy being a couple-dependent
outcome. Testing for trend was conducted based on the
linear trends of the association between BPA and
phthalate urinary biomarker concentrations across the
four intervals defined by their quartiles and the various
birth outcomes. We determined a significant linear
trend based on a two-sided p-value < 0.05. All analyses
were performed using SAS software (version 9.4; SAS
Institute, Cary, NC).
Results
The cohort comprised mostly non-Hispanic White men
and women who were college educated. The mean
female and male ages were 29.8 ± 3.7 and 31.5 ± 4.6 years,
respectively (Table 1). Prevalence of smoking and alco-
hol use at baseline was higher among males than females
(10 % vs 4 % and 87 % vs 78 %, respectively). The cohort
was largely healthy, except the slightly higher prevalence
of self-reported hypertension among males (8 % vs 3 %).
However, histories of chronic infection and diabetes
were < 1 % among couples.
The geometric means and accompanying 95 % CIs for
urinary BPA and phthalate metabolites for each partner
are displayed in Table 2. Overall, concentrations of BPA
and select phthalates (mEP, mEHP, mEHHP, mECPP,
mCMHP and mCPP) were significantly higher for males
than females (p < 0.05). Generally, the percentage of
urine samples with chemical concentrations below the
limit of detection (LOD) were uniform across parental
sex, with the exception of two chemicals, mMP and
mEHP, which were more readily detectible in male than
female urine samples (Table 2). Additionally, we assessed
the correlation coefficients for maternal and paternal
urinary BPA concentrations (r = 0.25), and the range of
correlation coefficients for the various phthalate metabo-
lites were between -0.03 to r = 0.33.
Birth outcomes were not statistically different by infant
sex, with the exception of birth weight (see Additional
file 1). Mean birth weight was 3313.7 ± 447.1 g among
girls and 3445.0 ± 488.7 g among boys (p = 0.03).
Although not statistically significant, the lower end of
the range of gestational age at birth was higher
among girls (173-290 days) compared with boy
infants (155-296). Additional details are provided in
Additional file 1.
Maternal urinary chemicals and birth outcomes
Overall, maternal biomarkers of preconception expo-
sures to non-persistent EDCs did not have a strong
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linear association with measures of birth size. Maternal
preconception urinary levels of BPA were not associated
with any birth size outcomes (see Additional file 2).
However, specific urinary levels for 8 out of 14 phtha-
lates were significantly associated with decrements in
birth size outcomes; importantly, no associations were
observed for 6 of the 14 phthalates (Table 3). Most
notably, negative associations were observed between
phthalate metabolites of low molecular weight mater-
nal compounds and birth weight. In adjusted models
including the sum of paternal chemicals, for the 2nd
versus 1st quartile of urinary mMP mean birth weight
was reduced by 177.6 g (95 % CI: -344.9, -10.3). Likewise,
for mothers in the 2nd versus 1st quartile of mEP a 200.2 g
(95 % CI: -386.9, -13.4) decrease in birth weight was
observed for infants. Overall, no associations were seen
for birth length with one exception. Specifically, when
comparing mothers in the 2nd and 3rd quartiles versus
the 1st quartile of mMP urinary concentrations a
reduction in birth length was observed (β = -1.45 cm;
95 % CI: -2.8, -0.1 and β = -1.57 cm; 95 % CI: -2.6,
-0.5, respectively) (Table 3). See Additional file 2 for
all associations between maternal urinary concen-
trations and birth size outcomes not achieving
statistical significance
Several phthalates were associated with reductions in
head circumference. Infants whose mothers had concen-
trations in the 3rd versus 1st quartile for mEP and mEOHP
had smaller head circumference (β = -1.4 cm; 95 % CI:
-2.3, -0.6 and β = -1.3 cm; 95 % CI: -2.2, -0.4, respectively)
(Table 3). Increasing maternal exposure to Di-2-ethylhexyl
phthalate (DEHP), as measured by the monoester
metabolite mECPP, was also associated with reduced
head circumference (β = -0.93 cm; 95 % CI: -1.8,-0.06),
when comparing women in the 2nd versus 1st quartile.
None of the chemicals were significantly associated
with ponderal indices when modeling maternal concen-
trations, including when further adjusting for paternal
concentrations.
Finally, maternal preconception urinary phthalate
metabolites were predominantly negatively associated
with gestational age at birth. The 2nd quartile of low
molecular weight metabolite mMP, previously described,
was associated with a 5.5 day (95 % CI: -10.0, -1.0) shorter
gestational age, compared with the 1st quartile (Table 3).
Contrarily, when comparing infants whose mothers
were in the 3rd versus 1st quartile of mEHP, a longer
gestational age (β = 5.7 days; 95 % CI: 0.5, 10.8) was
observed. With regard to high molecular weight
phthalate metabolites, the 2nd versus 1st quartile of
mOP was negatively associated with gestational age
(β = -5.2 days; 95 % CI: - 9.9, -0.4). Additionally, com-
paring the 4th and 1st quartiles of maternal mNP
reflected a significant 7- day (95 % CI: -12.3, -1.6)
reduction in gestational age. A significant (p = 0.02)
trend was observed between increasing quartiles of
mNP and mean change in gestational age (Table 3).
Paternal urinary chemicals and birth outcomes
With regard to paternal urinary phthalate concentra-
tions, few negative associations were observed in the
adjusted analysis, though different chemicals emerged.
Paternal 2nd quartile of mEHP concentrations were asso-
ciated with reduced birth weight when compared with
the 1st quartile (β = -191.9 g; 95 % CI: -381.6, -2.3)
(Table 4). Conversely, comparing the highest and the
lowest quartiles of paternal mCHP, a positive association
was observed with birth weight (β = 224.5 g; 95 % CI: 33.9,
415.0). An overall significant (p = 0.02) trend was
observed between increasing paternal quartiles of urin-
ary mCHP and mean change in birth weight.
Table 1 Socio-demographic comparison of partners with a
singleton live birth (n = 233),a LIFE Study
Characteristic Mothers Fathers
Age (years): mean ± SD† 29.8 ± 3.7 31.5 ± 4.6
Body mass index (kg/m2): mean ± SD† 26.4 ± 6.6 28.9 ± 4.7
Race/Ethnicity: n (%)
Non-Hispanic White 194 (84.0) 197 (84.9)
Non-Hispanic Black 2 (0.9) 4 (1.7)
Hispanic 20 (8.7) 20 (8.6)
Other 15 (6.4) 11 (4.8)
Education: n (%)
< High school 0 (0) 2 (0.9)
High school 9 (3.9) 5 (2.2)
College 222 (96.1) 224 (97.8)
Smoking status: n (%)†
Active (cotinine≥ 100 ng/ml) 11 (4.7) 24 (10.3)
Passive (cotinine < 100 ng/ml) 222 (95.3) 209 (89.7)
Alcohol use: n (%)†
No 52 (22.3) 31 (13.3)
Yes 181 (77.7) 201 (86.7)
History of diabetes: n (%)
No 232 (99.6) 232 (99.6)
Yes 1 (0.4) 1 (0.4)
History of hypertension: n (%)
No 226 (97.0) 213 (91.8)
Yes 7 (3.0) 19 (8.2)
History of chronic infections: n (%)
No 232 (99.6) 232 (99.6)
Yes 1 (0.4) 1 (0.4)
aMissing covariate data is not reflected in this table
†p < 0.05 from independent t-test for continuous characteristics or chi-square
test for categorical characteristics
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In contrast to the observations based upon maternal
urinary concentrations, the highest quartile of paternal
urinary BPA concentration was positively associated
with birth length (β = 1.4 cm; 95 % CI: 0.3, 2.5)
(Table 4). The overall trend also was observed to be
significant (p = 0.02) between increasing quartiles of
paternal BPA and mean change in birth length (Table 4).
A reduction in birth length was observed only between
the 2nd versus 1st paternal quartile of mOP (β = -1.2 cm;
95 % CI: -2.3, -0.1). No associations were observed
between paternal urinary chemicals and either head
circumference or ponderal index. However, urinary
phthalate metabolites were positively associated with
gestational age. Specifically, the 2nd and 3rd quartiles
of paternal mEOHP relative to the 1st quartile were
associated with a longer gestational age (β = 7.2 days;
95 % CI: 2.4, 12.1 and β = 5.1 days; 95 % CI: 0.02,
10.3, respectively, p for trend = 0.22). Likewise, the
2nd and 4th quartiles of mECPP were associated with
a longer gestational age (β = 7.3 days; 95 % CI: 2.0,
12.7 and β = 6.4 days; 95 % CI: 0.3, 12.5, respectively,
p for trend = 0.04). Finally, the 4th quartile of paternal
urinary concentrations of high molecular weight
metabolite mCHP was associated with a 7.0 day
(95 % CI = 2.2, 11.9) increase in gestational age,
compared with the lowest quartile; an overall trend
was observed for mean change in gestational age with
increasing urinary levels of mCHP (p for trend = 0.005).
Findings for paternal chemical concentrations and birth
outcomes not achieving significance are provided in
Additional file 3.
Discussion
In this analysis of couples’ preconception urinary con-
centrations of short-lived endocrine disrupting chemicals
and infant birth outcomes, we found parental urinary
biomarkers for BPA and phthalates to be predominantly
associated with reductions in length of gestation and
birth size in a non-linear manner. While many signals of
association were observed for specific quartiles of urin-
ary EDCs, an overall linear trend between increasing
biomarker quartiles and mean change in birth outcomes
was only observed for 4 of the 15 chemicals and no
chemical was consistently associated with reduction irre-
spective of parent. Specifically, we observed an overall
linear trend between quartiles of maternal mNP and
gestational age. Additionally, a linear trend was observed
between quartiles of paternal BPA and birth length,
Table 2 Geometric means (95 % CI) for maternal and paternal preconception urinary metabolite concentrations
Maternal urinary concentrations (n = 213) Paternal urinary concentrations (n = 211)
Chemical (ng/mL) LOD (ng/mL) % < LOD % Negative Geometric mean (95 % CI) % < LOD % Negative Geometric mean (95 % CI) pa
Creatinine 3.5 4.3 4.3 62.53 (55.7-70.2) 4.7 4.7 116 (106-128) <0.001
BPA 0.02 11 9.4 0.38 (0.31-0.45) 11 11 0.59 (0.49-0.71) 0.00
Low molecular weight
mMP 1.0 74 34 0.57 (0.44-0.76) 67 34 0.82 (0.64-1.07) 0.11
mEP 0.2 9.4 9.4 62.6 (50.3-77.9) 10 10 98.5 (78.4-124) 0.01
mBP 0.2 9.8 9.4 3.29 (2.75-3.94) 11 10 6.87 (5.76-8.19) 0.49
miBP 0.2 12 11 6.13 (5.15-7.29) 12 10 3.85 (3.27-4.54) 0.10
DEHP metabolites
mEHP 1.0 64 60 3.92 (2.90-5.31) 54 49 4.54 (3.39-6.08) 0.02
mEHHP 0.2 11 9.8 9.18 (7.56-11.1) 11 11 14.7 (11.8-18.2) 0.00
mEOHP 0.2 13 9.8 5.15 (4.13-6.42) 11 10 7.03 (5.67-8.70) 0.09
mECPP 0.2 11 9.4 13.4 (10.9-16.4) 10 10 18.9 (15.4-23.1) 0.02
mCMHP 0.2 9.8 9.4 9.38 (7.72-11.4) 11 11 18.9 (15.36-23.3) 0.00
High molecular weight
mBzP 0.2 13 9.8 2.90 (2.37-3.54) 14 11 3.40 (2.82-4.09) 0.32
mCHP 0.2 96 51 0.01 (0.01-0.02) 96 49 0.01 (0.01-0.02) 0.67
mOP 0.5 97 69 0.06 (0.04-0.08) 97 71 0.07 (0.04-0.10) 0.51
mCPP 0.2 14 9.8 3.12 (2.52-3.86) 14 11 5.47 (4.47-6.70 0.00
mNP 0.5 96 57 0.07 (0.05-0.09) 95 50 0.08 (0.06-0.11) 0.09
Abbreviations: BPA bisphenol (A; mMP monomethyl phthalate, mEP monoethyl phthalate, mBP mono-n-butyl phthalate, miBP monoisobutyl phthalate, mEHP mono-
ethylhexyl phthalate, mEHHP mono-(2-ethyl-5-hydroxyhexyl) phthalate, mEOHP mono-(2-ethyl-5-oxohexyl) phthalate, mECPP mono-(5-carboxy-2-ethylpentyl)
phthalate, mCMHP mono-[(2-carboxymethyl)hexyl] phthalate, mBzP monobenzyl phthalate, mCHP monocyclohexyl phthalate, mOP mono-n-octyl phthalate, mCPP
mono(3-carboxypropyl) phthalate, mNP monoisononyl phthalate
aReported p-values are from Wilcoxon-Mann–Whitney tests comparing the geometric means of maternal and paternal urinary chemical concentrations
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Table 3 Associations between quartiles of maternal urinary BPA and phthalate concentrations and mean change in birth outcomes
BW (g) BL (cm) HC (cm) PI (g/cm3) GA (days)
Chemical quartiles (ng/mL) β (95 % CI) β (95 % CI) β (95 % CI) β (95 % CI) β (95 % CI)
Low molecular weight
mMP
1st (≤ -0.004) Ref. Ref. Ref. Ref. Ref.
2nd (-0.001 - 0.33) −177.6 (-344.9, -10.3)* −1.6 (-2.6, -0.5)** −0.3 (-1.1, 0.6) 0.1 (-0.1, 0.2) −5.5 (-10.0, -1.0)*
3rd (0.34 - 1.68) −168.9 (-375.7, 37.9) −1.5 (-2.8, -0.1)* −0.4 (-1.3, 0.6) 0.1 (0.0, 0.3) −3.3 (-9.0, 2.5)
4th (≥1.69) −94.0 (-280.5, 92.4) −1.0 (-2.1, 0.1) −0.2 (-1.1, 0.8) 0.1 (-0.1, 0.2) −4.2 (-9.7, 1.4)
p-trend 0.94 0.33 0.70 0.34 0.45
mEP
1st (≤ 26.9) Ref. Ref. Ref. Ref. Ref.
2nd (27.3 - 65.3) −34.6 (-225.4, 156.2) −0.1 (-1.1, 1.0) −0.3 (-1.1, 0.5) 0.0 (-0.2, 0.2) 2.7 (-2.2, 7.5)
3rd (66.1 - 203) −200.2 (-386.9, -13.4)* −0.1 (-1.2, 0.9) −1.4 (-2.3, -0.6)** −0.1 (-0.3, 0.1) −1.8 (-6.6, 2.9)
4th (≥ 203) −72.1 (-287.5, 143.4) −0.3 (-1.5, 0.9) −0.6 (-1.6, 0.4) 0.0 (-0.2, 0.2) 0.6 (-4.9, 6.1)
p-trend 0.80 0.52 0.36 0.58 0.19
DEHP Metabolites
mEHP
1st (≤ -1.89) Ref. Ref. Ref. Ref. Ref.
2nd (-1.88 - -0.000716) 63.0 (-150.4, 276.3) 0.2 (-1.0, 1.3) 0.4 (-0.5, 1.3) 0.0 (-0.1, 0.1) 1.4 (-3.8, 6.6)
3rd (0.0340 - 3.73) 139.0 (-84.4, 362.5) 0.4 (-0.6, 1.4) 0.4 (-0.1, 1.5) 0.1 (-0.1, 0.2) 5.7 (0.5, 10.8)*
4th (≥ 3.81) 138.5 (-70.7, 347.6) 0.4 (-0.8, 1.6) −0.2 (-1.4, 1.0) 0.1 (-0.1, 0.2) 3.6 (-2.2, 9.5)
p-trend 0.09 0.37 0.81 0.20 0.10
mEOHP
1st (≤ 2.02) Ref. Ref. Ref. Ref. Ref.
2nd (2.03 - 6.14) −83.0 (-261.7, 95.8) −0.6 (-1.7, 0.5) −0.4 (-1.3, 0.5) 0.1 (-0.1, 0.2) −0.3 (-5.2, 4.6)
3rd (6.15 - 15.6) −162.4 (-350.4, 25.7) −0.5 (-1.7, 0.8) −1.3 (-2.2, -0.4)** 0.0 (-0.2, 0.1) 1.5 (-3.8, 6.7)
4th (≥ 15.8) 41.8 (-169.8, 253.5) −0.1 (-1.3, 1.2) −1.0 (-2.0, 0.1) 0.1 (-0.1, 0.2) 0.7 (-5.0, 6.4)
p-trend 0.43 0.93 0.18 0.21 0.56
mECPP
1st (≤ 5.70) Ref. Ref. Ref. Ref. Ref.
2nd (5.71 - 14.96) −154.4 (-331.2, 22.5) −0.5 (-1.6, 0.5) −0.9 (-1.8, -0.1)* 0.0 (-0.2, 0.2) 2.0 (-2.9, 6.9)
3rd (14.98 -36.3) −13.4 (-200.3, 173.5) −0.1 (-1.4, 1.2) −0.8 (-1.7, 0.2) 0.0 (-0.2, 0.2) 1.1 (-4.5, 6.7)
4th (≥ 36.7) 39.7 (-178.7, 258.1) 0.2 (-1.2, 1.7) −0.9 (-2.0, 0.2) 0.0 (-0.2, 0.2) 1.9 (-4.6, 8.4)
p-trend 0.40 0.74 0.20 0.53 0.47
mCMHP
1st (≤ 4.21) Ref. Ref. Ref. Ref.
2nd (4.22 - 11.3) −201.7 (-372.7, -30.7)** −1.1 (-2.2, 0.0) −0.2 (-1.1, 0.7) 0.0 (-0.1, 0.1) −1.4 (-6.8, 4.0)
3rd (11.4 - 30.0) −70.0 (-256.6, 118.7) −0.4 (-1.6, 0.8) −0.2 (-1.2, 0.9) 0.0 (-0.1, 0.2) 2.1 (-4.9, 9.1)
4th (≥ 30.03) 44.2 (-196.7, 285.1) −0.5 (-1.9, 1.0) −0.8 (-2.0, 0.3) 0.1 (-0.1, 0.4) 1.3 (-6.2, 8.8)
p-trend 0.68 0.38 0.19 0.14 0.65
High Molecular Weight
mOP
1st (≤ -0.110) Ref. Ref. Ref. Ref. Ref.
2nd (-0.111 - -0.0563) −215.4 (-387.1, -43.7)** −0.71 (-1.8, 0.4) −0.11 (-1.1, 0.8) 0.0 (-0.2, 0.1) 5.2 (-9.9, -0.4)*
3rd (-0.0564 - 0.022) −75.3 (-283.3, 132.6) −0.3 (-1.4, 0.8) −0.5 (-1.5, 0.5) 0.0 (-0.1, 0.2) −2.5 (-7.7, 2.7)
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mECPP and gestational age, and mCHP with birth
weight and gestational age. Furthermore, we found the
2nd quartiles of maternal mMP and mOP to be associ-
ated with a 5 day shorter length of gestation and a
178-215 g lowered birth weight. Similarly, the 4th
quartile of paternal mCHP was associated with the
longest increase in gestational age and the largest
increase in birth weight; this pattern was not observed
for every birth size and gestational age association. Even
with such large reductions in birth weight, there was no
hint of IUGR estimated by the Ponderal Index proxy.
Overall, urinary chemical concentrations in this study
population were lower than those reported for other
U.S. populations. For example, in our analysis cohort,
preconception urine concentrations of BPA had a
geometric mean of 0.38 ng/mL (95 % CI = 0.31 – 0.45)
for females and 0.59 (95 % CI = 0.49 – 0.71) for male
partners, whereas an analysis of urine samples from a
subset of the National Health and Nutrition Examination
Survey (NHANES) reported a geometric mean BPA of
1.74 (95 % CI = 1.55 – 1.95), 1.97 (95 % CI = 1.80-2.16),
and 1.73 (95 % CI = 1.60-1.87) μg/L for females and 2.09
(95 % CI = 1.92 – 2.28), 2.20 (95 % CI = 2.01-2.41), and
1.94 (95 % CI = 1.82-2.07) μg/L for males, during the
2005-2006, 2007-2008, and 2009-2010 study periods,
compared with our analysis cohort for which data was
also collected during the 2005-2009 period of time [36].
We are currently unaware of any previously published
work that has focused on preconception exposure to
BPA and phthalates as it relates to birth size precluding
a more complete interpretation of our findings. Our
findings are also limited by reliance on a single spot
urine collected at the time the couples began trying for
pregnancy. However, despite the low-to-moderate intra-
class correlation coefficients of EDCs (0.10-0.51) across
pregnancy [37], a single spot urine has the ability to be
predictive of exposure ranging from weeks to months
[38, 39]. Therefore our preconception urine samples of
BPA and phthalates may reflect chemical levels during
conception and possibly the first few weeks of preg-
nancy; a well-established critical window of fetal growth
and development. This assumption is further supported
by the concept of exposures to these non-persistent
chemicals being continual on a daily basis [40–42]. Still,
reliance on a single spot urine, whether collected prior
to conception or during pregnancy, may not adequate
characterize fetal exposure if one assumes changes in
routes of exposures during these sensitive windows at
any time, or if the many physiological changes required
to support and maintain pregnancy affect internal doses
and exposure quantification. Ideally, repeated samples
within and across sensitive windows should be a part
of future research methods to enable empirical asse-
ssment of exposure misclassification among other
related considerations.
Furthermore, our study is strengthened by our assess-
ment of paternal contribution to birth outcomes. Few epi-
demiological studies have been centered on paternal and/
or couples’ non-occupational exposure to environmental
chemicals as it relates to birth outcomes-none of which
investigated BPA or phthalates. Nevertheless, previous
analyses of maternal and paternal preconception expo-
sures to persistent chemicals such as polybrominated
diphenyl ethers and polychlorinated biphenyls and ob-
served similar reductions in birth weight (21 to 195 g)
[19], as did trace elements such as cesium, tungsten and
uranium for birth weight (1.11 to 1.30 cm) and length
(1.07 to 1.22 cm) [43]. Additionally, large effect estimates
of phthalates on birth weight (-177 to -215 g) resemble a
smoking during pregnancy effect [44, 45].
Still, cautious interpretation of results is warranted,
given the potential for competing risks since this analysis
Table 3 Associations between quartiles of maternal urinary BPA and phthalate concentrations and mean change in birth outcomes
(Continued)
4th (≥ 0.024) −81.8 (-251.7, 88.0) 0.12 (-0.9, 1.1) −0.74 (-1.7, 0.2) −0.1 (-0.2, 0.1) −4.9 (-10.0, 0.3)
p-trend 0.30 0.91 0.11 0.40 0.11
mNP
1st (≤ -0.079) Ref. Ref. Ref. Ref.
2nd (-0.0789 - -0.0006) −87.4 (-258.8, 83.9) −0.4 (-1.5, 0.6) 0.4 (-0.5, 1.3) 0.0 (-0.1, 0.2) −2.9 (-7.5, 1.7)
3rd (-0.0005 - 0.067) 53.9 (-126.1, 233.9) 0.7 (-0.5, 1.8) 0.1 (-0.9, 1.0) 0.0 (-0.2, 0.1) −4.0 (-9.0, 1.0)
4th (≥ 0.074) −149.8 (-327.4, 27.8) −0.1 (-1.2, 0.9) −0.1 (-1.0, 0.8) −0.1 (-0.2, 0.1) −7.0 (-12.3, -1.6)**
p-trend 0.30 0.95 0.98 0.40 0.02
NOTE: Significant findings are in boldface
Abbreviations: BW birth weight (grams), BL birth length (centimeters), HC head circumference (centimeters), PI Ponderal Index (grams/centimeters3), GA gestational
age (days), mMP monomethyl phthalate, mEP monoethyl phthalate, mEHP monoethylhexyl phthalate, mEOHP mono-(2-ethyl-5-oxohexyl) phthalate, mECPP mono-
(5-carboxy-2-ethylpentyl) phthalate, mCMHP mono-[(2-carboxymethyl)hexyl] phthalate, mOP mono-n-octyl phthalate, mNP monoisononyl phthalate
Models were adjusted for creatinine (ng/mL), age (years), race/ethnicity, BMI (kg/m2), education, cotinine (ng/mL), alcohol, conditional parity, infant gender,
chemical*gender, paternal chemicals
*p < 0.05 **p ≤ 0.01
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Table 4 Associations between quartiles of paternal urinary BPA and phthalate concentrations and mean change in birth outcomes
BW (g) BL (cm) HC (cm) PI (g/cm3) GA (days)
Chemical quartiles (ng/mL range) β (95 % CI) β (95 % CI) β (95 % CI) β (95 % CI) β (95 % CI)
BPA
1st (≤ 0.231) Ref. Ref. Ref. Ref. Ref.
2nd (0.234 - 0.501) 102.00 (-93.35, 297.96) 0.80 (-0.24, 1.84) 0.59 (-0.33, 1.50) −0.07 (-0.20, 0.07) 2.34 (-3.50, 8.18)
3rd (0.511- 1.13) 85.00 (-105.69, 276.23) 0.95 (-0.13, 2.03) 0.30 (-0.62, 1.22) −0.10 (-0.23, 0.03) 2.48 (-3.20, 8.15)
4th (≥ 1.14) 178.53 (-14.88, 371.94) 1.35 (0.25, 2.45)* 0.44 (-0.45, 1.33) −0.09 (-0.26, 0.07) 2.44 (-4.01, 8.90)
p-trend 0.07 0.02 0.34 0.25 0.44
DEHP Metabolites
mEHP
1st (≤ -1.44) Ref. Ref. Ref. Ref. Ref.
2nd (-1.38 - 1.23) −191.93 (-381.61, -2.25)* −0.59 (-1.62, 0.45) −0.76 (-1.64, 0.11) −0.08 (-0.21, 0.06) 0.64 (-4.18, 5.46)
3rd (1.253 - 5.26) −130.56 (-304.25, 43.13) −0.11 (-1.06, 0.84) −0.38 (-1.19, 0.43) −0.08 (-0.19, 0.04) 3.29 (-1.31, 7.9)
4th (≥ 5.42) 1.61 (-176.84, 180.06) −0.28 (-1.36, 0.8) −0.35 (-1.23, 0.52) 0.03 (-0.1, 0.16) 0.92 (-4.35, 6.18)
p-trend 0.99 0.61 0.43 0.61 0.73
mEOHP
1st (≤ 3.04) Ref. Ref. Ref. Ref. Ref.
2nd (3.06 - 6.93) −66.65 (-264.08, 130.78) −0.14 (-1.39, 1.1) −0.45 (-1.45, 0.55) −0.02 (-0.18, 0.13) 7.23 (2.36, 12.1)**
3rd (6.94 - 17.7) −48.23 (-266.56, 170.09) −0.09 (-1.41, 1.22) −0.55 (-1.49, 0.4) −0.02 (-0.19, 0.14) 5.13 (0.02, 10.25)*
4th (≥ 17.8) −65.30 (-317.61, 187.01) −0.58 (-2.04, 0.88) −0.56 (-1.56, 0.44) 0.05 (-0.1, 0.2) 3.22 (-1.96, 8.4)
p-trend 0.60 0.42 0.27 0.51 0.22
mECPP
1st (≤ 8.53) Ref. Ref. Ref. Ref. Ref.
2nd (8.60 - 20.2) −9.91 (-224.03, 204.22) −0.33 (-1.83, 1.17) −0.37 (-1.29, 0.55) 0.06 (-0.15, 0.27) 7.33 (1.95, 12.71)**
3rd (20.3 - 46.2) −13.26 (-217.02, 190.49) −0.18 (-1.55, 1.19) −0.15 (-1.18, 0.89) 0.00 (-0.22, 0.21) 5.08 (-0.57, 10.74)
4th (≥ 46.3) 7.90 (-235.19, 250.98) −0.77 (-2.56, 1.03) −0.35 (-1.4, 0.69) 0.14 (-0.07, 0.35) 6.38 (0.26, 12.5)*
p-trend 0.95 0.37 0.51 0.18 0.04
High Molecular Weight
mCHP
1st (≤ -0.0061) Ref. Ref. Ref. Ref. Ref.
2nd (-0.006 - 0.003) 45.51 (-130.2, 221.23) 0.59 (-0.42, 1.59) −0.04 (-0.88, 0.8) −0.06 (-0.18, 0.06) 3.22 (-1.34, 7.78)
3rd (0.0026 - 0.0145) 147.16 (-20.82, 315.14) 0.30 (-0.71, 1.31) 0.45 (-0.44, 1.35) 0.03 (-0.10, 0.15) 2.65 (-2.05, 7.34)
4th (≥ 0.0148) 224.45 (33.94, 414.96)* 0.92 (-0.13, 1.98) −0.52 (-1.32, 0.29) 0.03 (-0.10, 0.16) 7.01 (2.16, 11.86)**
p-trend 0.02 0.08 0.33 0.65 0.00
mOP
1st (≤ -0.115) Ref. Ref. Ref. Ref. Ref.
2nd (-0.114 - -0.0489) −173.71 (-347.54, 0.11) −1.22 (-2.33, -0.12)* −0.52 (-1.32, 0.29) 0.06 (-0.09, 0.2) −1.08 (-5.82, 3.67)
3rd (-0.0475 - 0.028) −67.62 (-257.73, 122.49) 0.21 (-0.89, 1.3) 0.26 (-0.62, 1.13) −0.08 (-0.20, 0.04) −4.07 (-9.04, 0.89)
4th (≥ 0.029) −64.61 (-243.21, 113.99) −0.54 (-1.6, 0.52) 0.17 (-0.77, 1.11) 0.00 (-0.13, 0.13) −1.29 (-6.13, 3.56)
p-trend 0.48 0.32 0.72 0.97 0.60
NOTE: Significant findings are in boldface
Abbreviations: BW birth weight (grams), BL birth length (centimeters), HC head circumference (centimeters), PI Ponderal Index (grams/centimeters3), GA gestational
age (days), BPA bisphenol (A), mEHP monoethylhexyl phthalate, mEOHP mono-(2-ethyl-5-oxohexyl) phthalate, mECPP mono-(5-carboxy-2-ethylpentyl) phthalate,
mCHP monocyclohexyl phthalate, mOP mono-n-octyl phthalate
Models were adjusted for creatinine (ng/mL), age (years), race/ethnicity, BMI (kg/m2), education, cotinine (ng/mL), alcohol, conditional parity, infant gender,
chemical*gender, maternal chemicals
*p < 0.05 **p ≤ 0.01
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was conditioned on having a live birth and EDCs have
also been reported to be associated with couples’ ability
to conceive [46]. However, the potential change in effect
estimates would be relatively small and adjusting for
common causes of the outcomes and fetal loss can
reduce negative bias [47]. We also acknowledge the
potential for spurious findings, given the comparison of
multiple outcomes and chemicals. However when con-
sidering type I error for this analysis, many of our find-
ings were statistically significant at with p-values ≤0.01,
which is a much smaller chance of falsely rejecting the
null hypothesis of no mean change in birth outcomes
per quartile increase of urinary chemical concentration,
compared with the lowest quartile of preconception
chemical. Imputation improved our precision, in that
significance was lower in our initial analyses without
imputation (data not shown). We also dichotomized
chemicals (mCHP and mOP) with a high percentage of
concentrations below the LOD at or below the 75th-
percentile, and observed similar results as when model-
ing machine observed concentrations suggesting
possible low dose effects. Despite these added analytic
steps, cautious interpretation is needed in the interpret-
ation of our findings as the findings await corroboration
in light of these and other study limitations such as a
relatively small cohort of infants and unknown birth out-
comes for couples exiting the study before delivery.
Furthermore, the presence of many low-level chemical
associations (2nd and 3rd quartiles) with birth size may
not simply be explained as the result of limited sample
size or overestimating the effect of urinary biomarkers of
exposure in light of exposure misclassification. A grow-
ing body of evidence suggests that the endocrine system
is sensitive to low-dose effects of various chemicals.
Furthermore, animal studies of EDCs that act as antian-
drogens or estrogen have shown that low-dose effects is
not only chemical specific but varies by endpoint as well
and may have global dynamic effects on cells, tissues
and organs [48–50].
While the biological explanation behind these findings
is not clearly understood, early pregnancy maternal
exposures to EDCs have been associated with oxidative
damage in rats, sheep and humans [51], and oxidative
stress has been shown to play a role in intrauterine
growth restriction (IUGR) [52, 53], and measures of fetal
anthropometry at birth have been established as proxies
for the assessment of IUGR. A previous analysis of
phthalates and oxidative stress among the present
cohort observed an increase in oxidative stress bio-
marker 8-hydroxy-2′-deoxyguanosine, with increased
urinary concentrations of select phthalate metabolites
[54]. We also consider the role of paternal exposures
[55] found male urinary concentrations of select
phthalate metabolites to be associated with diminished
fecundity as measured by a longer time-to-pregnancy
(TTP), although female urinary phthalate exposures
were not associated with a longer TTP. DNA methyla-
tion is also suspected to affect select growth genes as a
result of first trimester maternal phthalate exposure
[56]. Animal studies suggest that DNA methylation
may play a role in short-lived EDCs transgenerational
epigenetic effects, which result in adverse reproductive
outcomes in later offspring generations [57, 58]. A
recent study of male mice exposed to dioxin found that
even when mated with non-exposed female mice, mul-
tiple subsequent generations presented with reduced
fertility and spontaneous preterm birth [59]. Addition-
ally, male offspring of mice in one study had increased
spermatogenic cell apoptosis and differential DNA
methylation regions in the offspring sperm were con-
sistent with a specific exposure lineage back to the ori-
ginal exposure of the first generation male mouse [60].
Conclusions
To our knowledge, this study represents an initial attempt
to utilize a couple-based exposure design to assess the
relation between maternal and paternal preconception
urinary concentrations of BPA and phthalates and infant
gestation and birth size. In the context of an observational
design and exploratory analytic strategy, we observed
some evidence that BPA and some but not all phthalates
were associated with shorter gestations and smaller infants
in relation to maternal exposure, but longer gestations
and larger infants in relation to paternal exposures.
Collectively, the findings underscore the importance of
couple based designs for assessing the reproductive and/
or developmental toxicity of environmental phenols and
other endocrine disrupting chemicals.
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